CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Diclofenac Sodium

Diclofenac· ingredient diclofenacAcetic acid derivatives and related substances· DICLOFENAC SODIUM 20 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.39681
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per GM — the trend nobody else shows. 7 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other diclofenac products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.

ProductNADAC / GMvs this
Diclofenac Sodium Delayed Release$0.06665−$0.33020
Diclofenac DR$0.06665−$0.33020
Aleve Arthritis Pain Gel$0.08776−$0.30900
Diclofenac Potassium$0.09863−$0.29820
Clofenax$0.12486−$0.27200
Diclofenac Sodium$0.36949−$0.02730
Diclofenac Sodium Delayed Release$0.72051+$0.32370
Diclofenac Sodium ER$0.73145+$0.33460

Medicare Part D coverage · CY2026

On 82 plan formularies · typical tier 5
Prior auth 72% · Step therapy 0% · Quantity limit 100% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.